November 12, 2026 · JAMA · DOI: 10.1001/jama.2026.20250

Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial.

Listen to this summary

This phase 3 randomized trial asked whether izalontamab brengitecan, an EGFR/HER3 bispecific antibody-drug conjugate, improves outcomes versus physician-selected chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma that progressed after first-line PD-1/PD-L1 inhibitor plus platinum chemotherapy. In 497 patients across 80 Chinese hospitals, izalontamab brengitecan significantly prolonged progression-free survival (median 4.17 vs 1.97 months; HR 0.50) and overall survival (median 9.79 vs 7.20 months; HR 0.63), at the cost of more frequent grade 3 or higher treatment-related adverse events (85.1% vs 59.3%, mostly hematologic). The authors conclude that izalontamab brengitecan may serve as a new second-line treatment for this population in China.

Zhihao Lu, Zhangzhou Huang, Xiangjiao Meng, Yun Fan, Tao Wu, Qingsong Pang, Feng Wang, Yanqiao Zhang, Shegan Gao, Tianshu Liu, Jin Zhou, Yong Fang, Ning Li, Wei Li, Guochun Cao, Shoubing Zhou, Na Li, Feng Ye, Yinghua Ji, Jingdong Zhang, Xuwei Cai, Jianping Xiong, Mingjun Zhang, Lixin Wan, Yanhong Gu, Hui Luo, Xiaotian Zhang, Jinglei Qu, Wenhui Yang, Jianzhong Cao, Xueqiang Zhu, Jiayan Chen, Tienan Yi, Yongli Gao, Jiangqiong Huang, Zhenhua Liu, Jun Wang, Fang Ma, Yan Luo, Xuelei Ma, Jianfei Fu, Shubo Ding, Yu Liu, Sa Xiao, Hai Zhu, Yi Zhu, Lin Shen

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play